Non-small Cell Lung Cancer Stage IV Clinical Trial
Official title:
Maintenance Metronomic Per OS Navelbine In Advanced NSCLC Patients After Previous Platinum Based Chemotherapy: A Multicenter Randomized Best Supportive Care Controlled Phase II Study - MA.NI.LA. Trial
Non Small Cell Lung Cancer (NSCLC) represents the first cancer related cause of death
worldwide with 1.4 millions of deaths every years. Current standard therapies include
platinum-containing drugs but at one year from diagnosis the survival rate is still low
(30-40%) .
The purpose of this study is to evaluate the role of a platinum-free drug, named Vinorelbine,
administered by the so called "metronomic schedule" in order to prolong the progression free
survival of patients.
Systemic therapy remains the mainstay of treatment of advanced stage NSCLC. Combination
chemotherapy with a platinum-based regimen has emerged as standard therapy for patients with
advanced stage disease. Observations supported by the findings of several clinical trial,
established the notion that an efficacy plateau had been reached in advanced stage NSCLC
patients treated with platinum-containing drugs.
Recent phase III trials suggest the benefit of "switch" and "continuing" maintenance
treatment with different drugs. As "switched therapy", Vinorelbine has been selected on the
base of its anti-mitotic role. In fact, the use of anti-mitotic drugs at lower dose but with
higher frequency (metronomic schedule) seems to augment the anti-angiogenetic effect of this
kind of drugs, thus augmenting the efficacy of the therapy.
Therefore, the purpose of the current study is to evaluate the role of a "switched
maintenance" with oral vinorelbine administered as a metronomic schedule in terms of
Progression Free Survival (PFS) in advanced NSCLC patients with stable disease after first
line platinum based chemotherapy.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02047344 -
Efficacy, Safety and Pharmacokinetics Study of Antroquinonol to Treat NSCLC
|
Phase 2 | |
| Terminated |
NCT00766246 -
Phase II Avastin Trial for Stage IIIB/IV NSCLC
|
Phase 2 | |
| Active, not recruiting |
NCT04108026 -
Immunotherapy in Patient With Poor General Condition
|
Phase 2 | |
| Active, not recruiting |
NCT04432207 -
A Study of IMU-201 (PD1-Vaxx), a B-Cell Immunotherapy, in Adults With Non-Small Cell Lung Cancer
|
Phase 1 | |
| Recruiting |
NCT05598853 -
Intrathecal Double Checkpoint Inhibition
|
Phase 1 | |
| Not yet recruiting |
NCT06117644 -
The Efficacy of Double-dose Furmonertinib in the Treatment of Patients With Slow Osimertinib-resistant NSCLC
|
||
| Terminated |
NCT01348126 -
Study of Ganetespib (STA-9090) + Docetaxel in Advanced Non Small Cell Lung Cancer
|
Phase 2/Phase 3 | |
| Completed |
NCT01086254 -
SAR240550 in Combination With Gemcitabine/Cisplatin in Non-small Cell Lung Cancer
|
Phase 2 | |
| Terminated |
NCT01798485 -
A Phase 3 Study of Ganetespib in Combination With Docetaxel Versus Docetaxel Alone in Patients With Advanced NSCLC
|
Phase 3 | |
| Recruiting |
NCT06348199 -
A Study to Compare the Efficacy, Safety, Pharmacokinetics, and Immunogenicity Between SB27 and Keytruda in Subjects With Metastatic Non-squamous Non-small Cell Lung Cancer
|
Phase 3 | |
| Terminated |
NCT04289259 -
Tumor Mutational Burden in Lung Cancer Patients
|
||
| Recruiting |
NCT05818449 -
Improvement of Personalized Lung Cancer Care Through Digital Connection and Patient Participation (DigiNet)
|
N/A | |
| Completed |
NCT03526900 -
Atezolizumab in Combination With Carboplatin Plus Pemetrexed in Chemotherapy-naïve Patients With Asymptomatic Brain Metastasis
|
Phase 2 | |
| Terminated |
NCT03275597 -
Phase Ib Study of Stereotactic Body Radiotherapy (SBRT) in Oligometastatic Non-small Lung Cancer (NSCLC) With Dual Immune Checkpoint Inhibition
|
Phase 1 | |
| Completed |
NCT02450539 -
A Study of Abemaciclib (LY2835219) in Participants With Stage IV Squamous Non-small Cell Lung Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT05055167 -
Envafolimab as First-line Treatment of Aged Patients in Advanced NSCLC
|
Phase 2 | |
| Not yet recruiting |
NCT03543683 -
Combination of Osimertinib and Aspirin to Treat 1st Generation EGFR-TKI Resistance in NSCLC
|
||
| Not yet recruiting |
NCT03532698 -
Combination of Osimertinib and Aspirin to Treat Osimertinib Resistance Non-small Cell Lung Cancer ( NSCLC)
|